ArticleCVIR endovascular2025
Single center experience with a novel single-branched thoracic stent graft.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThoracic endovascular aortic repair (TEVAR) has been a feasible treatment option since the first stent graft was approved by the FDA in 2005, and is now the recommended method for treating most descending aorta pathology in the current clinical practice guidelines. Indications for TEVAR include descending aorta aneurysms, traumatic aortic injury and pathology that presents as acute aortic syndrome. More often than not the lesion that needs to be excluded is quite close or contains the distal aortic arch, thus requiring the coverage of the left subclavian artery (LSA) origin, a practice that has been associated with severe complications. Contraindications to LSA coverage resulted in the development of various surgical and endovascular LSA revascularization techniques. MATERIALS AND
methodsBranched stent grafts containing a single branch for the LSA are a rapidly evolving technology regarding LSA reconstruction during TEVAR. The aim of this article is to demonstrate our center's experience using a novel off-the-shelf single-branched stent graft, the GORE® TAG® Thoracic Branch Endoprosthesis (TBE) (W. L. Gore & Associates, Inc, Flagstaff, Ariz, USA). The GORE® TAG® TBE is commercially available in Europe since early 2024. We have so far, since February 2024, treated 12 patients using this endograft, successfully treating all types of aortic lesions.
conclusionsBranched TEVAR is becoming a feasible option for treating descending aorta pathology, without covering the LSA. Moreover, the development of off-the-shelf branched stent grafts, enables physicians to treat patients in the emergency setting, aside from planned procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.